Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lowered its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 7.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,847 shares of the medical device company’s stock after selling 770 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Tandem Diabetes Care were worth $418,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of TNDM. GAMMA Investing LLC lifted its position in shares of Tandem Diabetes Care by 11.2% during the second quarter. GAMMA Investing LLC now owns 4,276 shares of the medical device company’s stock worth $172,000 after purchasing an additional 431 shares in the last quarter. MN Wealth Advisors LLC grew its position in shares of Tandem Diabetes Care by 3.1% during the second quarter. MN Wealth Advisors LLC now owns 14,723 shares of the medical device company’s stock worth $593,000 after buying an additional 440 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Tandem Diabetes Care by 29.2% in the 2nd quarter. Signaturefd LLC now owns 2,307 shares of the medical device company’s stock valued at $93,000 after purchasing an additional 522 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Tandem Diabetes Care by 4.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,960 shares of the medical device company’s stock worth $603,000 after purchasing an additional 592 shares during the last quarter. Finally, Assetmark Inc. acquired a new stake in Tandem Diabetes Care in the third quarter valued at $29,000.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now directly owns 195,190 shares of the company’s stock, valued at approximately $5,855,700. This trade represents a 4.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on TNDM. Barclays increased their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. UBS Group raised Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Sanford C. Bernstein began coverage on shares of Tandem Diabetes Care in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price target for the company. Royal Bank of Canada assumed coverage on shares of Tandem Diabetes Care in a research report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 price objective on the stock. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $45.00 target price on shares of Tandem Diabetes Care in a research note on Monday, September 23rd. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $54.25.

Tandem Diabetes Care Stock Performance

TNDM opened at $31.22 on Thursday. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The stock has a market cap of $2.05 billion, a P/E ratio of -15.56 and a beta of 1.36. Tandem Diabetes Care, Inc. has a 1-year low of $18.45 and a 1-year high of $53.69. The stock’s 50 day simple moving average is $35.65 and its 200 day simple moving average is $41.04.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The business had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. During the same period in the previous year, the firm earned ($0.38) EPS. The business’s revenue for the quarter was up 31.4% compared to the same quarter last year. As a group, equities analysts anticipate that Tandem Diabetes Care, Inc. will post -1.73 EPS for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.